Dr Reddy's Laboratories among other generic pharma companies in US to face antitrust litigation

"The complaint, which purports to be on behalf of a class of indirect purchasers, asserts claims under federal and state antitrust laws and other state laws alleging that the defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation," PTI quoted Dr Reddy's Laboratories as saying.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0aGXqzr
via IFTTT